FluoGuide Company Description

FluoGuide A/S, a clinical stage biotechnology company, focuses on developing drugs for surgical outcomes by making cancer fluorescent in Denmark.

Its lead product candidate is FG001, which is in Phase IIa and IIb for the treatment of high-grade glioma; Phase II clinical trial for the treatment of lung cancer, and head and neck cancer.

The company has a collaboration agreement with ZEISS Medical Technologies for the development of FG001 for tumor imaging and surgical margins assessment for head and neck cancer.

FluoGuide A/S was incorporated in 2018 and is headquartered in Copenhagen, Denmark.

FluoGuide A/S

Country	Denmark
Founded	2018
Industry	Biotechnology
Sector	Healthcare
Employees	8
CEO	Morten Albrechtsen

Contact Details

Address: Ole Maaløes Vej 3 Copenhagen, 2200 Denmark
Phone	45 31 22 66 60
Website	fluoguide.com

Stock Details

Ticker Symbol	FLUO
Exchange	Nasdaq Stockholm
Fiscal Year	January - December
Reporting Currency	DKK
ISIN Number	DK0061123312
SIC Code	2836

Key Executives

Name	Position
Morten Albrechtsen B.B.A., BBA, M.D.	Chief Executive Officer
Ole Larsen Cand. merc., M.Sc.	Chief Financial Officer
Donna Haire	Chief Operating Officer
Prof. Andreas Kjaer M.D., M.Sc., Ph.D.	CSO, Head of Scientific Advisory Board and Director
Dr. Grethe Nørskov Rasmussen M.Sc., Ph.D.	Chief Development Officer
Dr. Jens Ellrich M.D., Ph.D.	Chief Medical Officer
Dorthe Gronnegaard Mejer	Vice President of Clinical Development